Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.116024 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Adrien Rousseau und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, Ligue Contre le Cancer…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androstenes, Prednisone, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Fonds d'Etudes et de Recherche du Corps Medical.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, Ligue Contre le Cancer, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, Fran…
- Oncostat U1018, Inserm, Ligue Contre le Cancer, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France; Department of Biostatistics and Epidemiology, Institut Gustave Roussy, University of Paris-Saclay,…
- Department of Medicine, Institut Bergonié, Bordeaux, France.
- Department of Radiotherapy, Vall d'Hebron University Hospital, Barcelona, Spain.
- Department of Radiotherapy, Institut de Cancérologie de l'Ouest René Gauducheau, Saint Herblain, France.
- Cancer Trials Ireland, Dublin, Ireland; St Vincents University Hospital, Dublin, Ireland.
Förderung
- Fonds d'Etudes et de Recherche du Corps Medical
Zitieren
APA
Rousseau, A., Karimi, M., Michiels, S., Roubaud, G., Maldonado, X., Supiot, S., McDermott, R., Flechon, A., Tombal, B., Ronchin, P., Berthold, D., Berdah, J. F., Kacso, G., Gravis, G., Calabro, F., Tartas, S., Muracciole, X., Ribault, H., Fizazi, K., & Foulon, S. (2025). Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116024
Vancouver
Rousseau A, Karimi M, Michiels S, Roubaud G, Maldonado X, Supiot S, et al. Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.116024
BibTeX
@article{Rousseau2025,
author = {Rousseau, Adrien and Karimi, Maryam and Michiels, Stefan and Roubaud, Guilhem and Maldonado, Xavier and Supiot, Stephane and McDermott, Ray and Flechon, Aude and Tombal, Bertrand and Ronchin, Philippe and Berthold, Dominik and Berdah, Jean-François and Kacso, Gabriel and Gravis, Gwenaelle and Calabro, Fabio and Tartas, Sophie and Muracciole, Xavier and Ribault, Helene and Fizazi, Karim and Foulon, Stéphanie},
title = {Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.116024}
}
EUVIMED